Healthy adolescents and adults post nonavalent human papillomavirus vaccination. Human papillomavirus (HPV) HPV vaccine antibody neutralizing antibody
Conditions
Interventions
Female received 2 doses of 9-valent HPV vaccine,Female received 3 doses of 9-valent HPV vaccine,Male received 2 doses of 9-valent HPV vaccine,Male received 3 doses of 9-valent HPV vaccine
Female 2 doses,Female 3 doses,Male 2 doses,Male 3 doses
Sponsors
Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
9 Years to 26 Years
Inclusion criteria
Inclusion criteria: 1. Healthy participants aged 9-26 years old. 2. Received 2-3 doses of 9-valent HPV vaccine for 1-18 months. 3. The participant has signed an assent/consent form and/or parent(s) or legally authorized representative(s) (LAR) have signed and dated a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have immunocompromised condition. 2. Ever received immunosuppressive medications at the time of HPV vaccination to participating in this study. 3. Receipt of immunoglobulins or blood products within 3 months. 4. Received any vaccine within 2 weeks or 4 weeks for live vaccine. 5. Have history of HPV-related precancerous lesion or cancer. 6. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutralizing antibody to HPV-6, 11, 16, 18, 31, 33, 45, 52, 58 At enrollment Pseudovirus-based neutralization assay (PBNA) | — |
Secondary
| Measure | Time frame |
|---|---|
| Antibody to to HPV-6, 11, 16, 18, 31, 33, 45, 52, 58 At enrollment ELISA | — |
Countries
Thailand
Contacts
Public ContactDr. Napaporn Chantasrisawad
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed